Switch theme
Sign up to access all valuation multiples
Onconic Therapeutics Inc is a company that researches and develops new drugs for gastrointestinal diseases and anticancers, which have large unmet medical needs. Its pipeline products are Zataprazan(OCN-101) and OCN-201.
2020
n/a
Last FY Revenue $10.8M
Last FY EBITDA -$6.4M
$141M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Onconic Therapeutics achieved revenue of $10.8M and an EBITDA of -$6.4M.
Onconic Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Onconic Therapeutics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $10.8M | XXX | XXX | XXX |
| Gross Profit | XXX | $10.8M | XXX | XXX | XXX |
| Gross Margin | XXX | 100% | XXX | XXX | XXX |
| EBITDA | XXX | -$6.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -59% | XXX | XXX | XXX |
| EBIT | XXX | -$3.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | -32% | XXX | XXX | XXX |
| Net Profit | XXX | -$5.9M | XXX | XXX | XXX |
| Net Margin | XXX | -55% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Onconic Therapeutics's stock price is KRW 22000 (or $16).
Onconic Therapeutics has current market cap of KRW 238B (or $173M), and EV of KRW 193B (or $141M).
See Onconic Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $141M | $173M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Onconic Therapeutics has market cap of $173M and EV of $141M.
Onconic Therapeutics's trades at 13.0x EV/Revenue multiple, and -21.9x EV/EBITDA.
Equity research analysts estimate Onconic Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Onconic Therapeutics's P/E ratio is not available.
See valuation multiples for Onconic Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $173M | XXX | $173M | XXX | XXX | XXX |
| EV (current) | $141M | XXX | $141M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -21.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -40.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -29.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -24.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOnconic Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Onconic Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Onconic Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Onconic Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -59% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 74% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 132% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Onconic Therapeutics acquired XXX companies to date.
Last acquisition by Onconic Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Onconic Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Onconic Therapeutics founded? | Onconic Therapeutics was founded in 2020. |
| Where is Onconic Therapeutics headquartered? | Onconic Therapeutics is headquartered in South Korea. |
| Is Onconic Therapeutics publicy listed? | Yes, Onconic Therapeutics is a public company listed on KRX. |
| What is the stock symbol of Onconic Therapeutics? | Onconic Therapeutics trades under 476060 ticker. |
| When did Onconic Therapeutics go public? | Onconic Therapeutics went public in 2024. |
| Who are competitors of Onconic Therapeutics? | Similar companies to Onconic Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Onconic Therapeutics? | Onconic Therapeutics's current market cap is $173M |
| Is Onconic Therapeutics profitable? | Yes, Onconic Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
